Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators..

Lancet. 2010 Mar 6;375(9717):807-15. doi: 10.1016/S0140-6736(09)62125-5.

PMID:
20206776
2.

Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery.

Deeks ED.

Drugs. 2012 Jun 18;72(9):1271-91. doi: 10.2165/11209020-000000000-00000. Review.

PMID:
22686618
3.

Apixaban. After hip or knee replacement: LMWH remains the standard treatment.

[No authors listed]

Prescrire Int. 2012 Sep;21(130):201-2, 204. Review.

PMID:
23016247
4.

The role of apixaban for venous and arterial thromboembolic disease.

Prom R, Spinler SA.

Ann Pharmacother. 2011 Oct;45(10):1262-83. doi: 10.1345/aph.1Q119. Epub 2011 Sep 27. Review.

PMID:
21954450
5.

Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review.

Maniscalco P, Caforio M, Imberti D, Porcellini G, Benedetti R.

Clin Appl Thromb Hemost. 2015 Mar;21(2):115-9. doi: 10.1177/1076029614546328. Epub 2014 Aug 13. Review.

PMID:
25125051
6.

Practical use of apixaban in the prevention of venous thromboembolism after total knee or hip replacement.

Lassen MR.

Drugs Today (Barc). 2012 Apr;48(4):249-58. doi: 10.1358/dot.2012.48.4.1738052. Review.

PMID:
22536567
7.

Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.

Squizzato A, Lussana F, Cattaneo M.

Thromb Haemost. 2015 Aug;114(2):237-44. doi: 10.1160/TH15-01-0073. Epub 2015 May 7. Review.

PMID:
25946985
8.

Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.

Martin MT, Nutescu EA.

Curr Med Res Opin. 2011 Nov;27(11):2123-31. doi: 10.1185/03007995.2011.619178. Epub 2011 Sep 23. Review.

PMID:
21942466
9.

Apixaban: a new player in the anticoagulant class.

Agrawal R, Jain P, Dikshit SN.

Curr Drug Targets. 2012 Jun;13(6):863-75. Review.

PMID:
22250655
10.

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.

Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E.

BMJ. 2012 Jun 14;344:e3675. doi: 10.1136/bmj.e3675. Review.

11.

Apixaban: an oral direct factor-xa inhibitor.

Jiménez D, Yusen RD, Ramacciotti E.

Adv Ther. 2012 Mar;29(3):187-201. doi: 10.1007/s12325-012-0003-2. Epub 2012 Feb 17. Review.

PMID:
22354465
12.

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.

Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Review.

13.

Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Burness CB, McKeage K.

Drugs. 2012 May 7;72(7):963-86. doi: 10.2165/11209080-000000000-00000. Review.

PMID:
22564134
14.

Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.

Yoshida Rde A, Yoshida WB, Maffei FH, El Dib R, Nunes R, Rollo HA.

Ann Vasc Surg. 2013 Apr;27(3):355-69. doi: 10.1016/j.avsg.2012.06.010. Epub 2013 Jan 23. Review.

PMID:
23351997
15.

Apixaban: A Review in Venous Thromboembolism.

Greig SL, Garnock-Jones KP.

Drugs. 2016 Oct;76(15):1493-1504. Review.

PMID:
27653758
16.

Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.

Duggan ST.

Am J Cardiovasc Drugs. 2012 Feb 1;12(1):57-72. doi: 10.2165/11208470-000000000-00000. Review.

PMID:
22272729
17.

Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.

Albertsen IE, Larsen TB, Rasmussen LH, Overvad TF, Lip GY.

Drugs. 2012 Sep 10;72(13):1755-64. doi: 10.2165/11635630-000000000-00000. Review.

PMID:
22876779
18.

A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists.

Touma L, Filion KB, Atallah R, Eberg M, Eisenberg MJ.

Am J Cardiol. 2015 Feb 15;115(4):533-41. doi: 10.1016/j.amjcard.2014.11.039. Epub 2014 Dec 2. Review.

PMID:
25547937
19.

Apixaban in Venous Thromboembolism in an Era of New Oral Anticoagulants.

Turagam MK, Velagapudi P, Bongu N, Chinnakotla B, Kocheril A.

Cardiovasc Hematol Disord Drug Targets. 2015;15(2):139-47. Review.

PMID:
26126820
20.

New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies.

Turpie AG, Eriksson BI, Bauer KA, Lassen MR.

Chest. 2003 Dec;124(6 Suppl):371S-378S. Review.

PMID:
14668420

Supplemental Content

Support Center